WO2006074891A3 - Proteines contenant des lymphocytes t regulateurs et destinees au traitement et au diagnostic de maladies - Google Patents
Proteines contenant des lymphocytes t regulateurs et destinees au traitement et au diagnostic de maladies Download PDFInfo
- Publication number
- WO2006074891A3 WO2006074891A3 PCT/EP2006/000122 EP2006000122W WO2006074891A3 WO 2006074891 A3 WO2006074891 A3 WO 2006074891A3 EP 2006000122 W EP2006000122 W EP 2006000122W WO 2006074891 A3 WO2006074891 A3 WO 2006074891A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- illnesses
- diagnosis
- therapy
- proteins containing
- cells
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 210000003289 regulatory T cell Anatomy 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 230000006020 chronic inflammation Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000003669 immune deficiency disease Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464839—Allergens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Rehabilitation Therapy (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne de nouvelles protéines contenant des lymphocytes T régulateurs correspondant à la séquence d'acide aminé (voir SEQ ID No. 1-27) comme telle, notamment leur utilisation comme marqueurs ainsi que et pour le traitement et le diagnostic de maladies, notamment d'allergies, de maladies auto-immunes, notamment l'arthrite rhumatoïde, la sclérose en plaques ou la maladie de Crohn, l'inflammation chronique, l'asthme, les maladies d'immuno-déficience, le sida les rejets de greffes et les maladies cancéreuses comme le diabète.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005002110.7 | 2005-01-17 | ||
DE102005002110A DE102005002110A1 (de) | 2005-01-17 | 2005-01-17 | Regulatorische-T-Zellen enthaltend Proteine zur Therapie und Diagnose von Erkrankungen |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006074891A2 WO2006074891A2 (fr) | 2006-07-20 |
WO2006074891A3 true WO2006074891A3 (fr) | 2007-01-04 |
Family
ID=36127913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/000122 WO2006074891A2 (fr) | 2005-01-17 | 2006-01-10 | Proteines contenant des lymphocytes t regulateurs et destinees au traitement et au diagnostic de maladies |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE102005002110A1 (fr) |
WO (1) | WO2006074891A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007041657A1 (de) * | 2007-09-03 | 2009-03-05 | Protagen Ag | Markersequenzen für Multiple Sklerose und deren Verwendung |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003008558A2 (fr) * | 2001-07-20 | 2003-01-30 | University Of Iowa Research Foundation | Clones d'hybridomes inhibiteurs cd4?+cd25+¿ |
WO2003077872A2 (fr) * | 2002-03-15 | 2003-09-25 | Attenuon, Llc | Tropomyosine de surface cellulaire servant de cible de l'inhibition de l'angiogenese |
WO2005007836A1 (fr) * | 2003-07-15 | 2005-01-27 | Protagen Ag | Lymphocytes t regulateurs contenant de la galectine pour le traitement et le diagnostic de maladies |
WO2005070090A2 (fr) * | 2004-01-08 | 2005-08-04 | Regents Of The University Of California | Lymphocytes t regulateurs supprimant l'auto-immunite |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1241249A1 (fr) * | 2001-03-12 | 2002-09-18 | Gerold Schuler | Lymphocytes T CD4+CD25+ régulateurs provenant du sang humain |
-
2005
- 2005-01-17 DE DE102005002110A patent/DE102005002110A1/de not_active Withdrawn
-
2006
- 2006-01-10 WO PCT/EP2006/000122 patent/WO2006074891A2/fr not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003008558A2 (fr) * | 2001-07-20 | 2003-01-30 | University Of Iowa Research Foundation | Clones d'hybridomes inhibiteurs cd4?+cd25+¿ |
WO2003077872A2 (fr) * | 2002-03-15 | 2003-09-25 | Attenuon, Llc | Tropomyosine de surface cellulaire servant de cible de l'inhibition de l'angiogenese |
WO2005007836A1 (fr) * | 2003-07-15 | 2005-01-27 | Protagen Ag | Lymphocytes t regulateurs contenant de la galectine pour le traitement et le diagnostic de maladies |
WO2005070090A2 (fr) * | 2004-01-08 | 2005-08-04 | Regents Of The University Of California | Lymphocytes t regulateurs supprimant l'auto-immunite |
Non-Patent Citations (3)
Title |
---|
JONULEIT H ET AL: "The regulatory T cell family : Distinct subsets and their interrelations", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 171, December 2003 (2003-12-01), pages 6323 - 6327, XP002270348, ISSN: 0022-1767 * |
LUTTER P ET AL: "Proteome analysis of regulatory T cells: Promising targets for innovative immunotherapeutical approaches.", MOLECULAR & CELLULAR PROTEOMICS, vol. 2, no. 9, September 2003 (2003-09-01), & HUPO (HUMAN PROTEOMICS ORGANISATION) 2ND ANNUAL AND IUBMB (INTERNATIONAL UNION OF BIOCHEMISTRY AND M; MONTREAL, QUEBEC, CANADA; OCTOBER 08-11, 2003, pages 990, XP002377180, ISSN: 1535-9476 * |
STASSEN MICHAEL ET AL: "Human CD25+ regulatory T cells: two subsets defined by the integrins alpha4beta7 or alpha4beta1 confer distinct suppressive properties upon CD4+ T helper cells", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 34, no. 5, May 2004 (2004-05-01), pages 1303 - 1311, XP002377231, ISSN: 0014-2980 * |
Also Published As
Publication number | Publication date |
---|---|
WO2006074891A2 (fr) | 2006-07-20 |
DE102005002110A1 (de) | 2006-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006119170A3 (fr) | Utilisation de peptides derives de cytokine pour traiter la douleur et une maladie neurodegenerative | |
WO2005019258A3 (fr) | Compositions et methodes de traitement de maladies relatives au systeme immunitaire | |
WO2004039956A3 (fr) | Compositions et methodes de traitement de maladies liees au systeme immunitaire | |
NZ621196A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
WO2005103712A3 (fr) | Utilisation de precurseurs de tachykinines et/ou de fragments de celles-ci dans un diagnostic medical | |
WO2008106980A3 (fr) | Anticorps recombinants pour le traitement des infections au virus respiratoire syncytial | |
WO2007147019A3 (fr) | Antagonistes d'il-17 et d'il-23 et leurs procédés d'utilisation | |
EP2527369A3 (fr) | Anticorps monoclonal anti-bêta-amyloide (abêta) et ses utilisations | |
WO2004078777A3 (fr) | Proteines protegees contre la dipeptidylpeptidase | |
IL195338A (en) | An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use | |
WO2008060364A3 (fr) | Anticorps | |
EP2628749A3 (fr) | Compositions de chémokine antimicrobiennes et procédés dýutilisation | |
NO330984B1 (no) | Aminosyre-fenoksyestere, fremgangsmate for fremstilling av slike, mellomprodukter i synteseveien, farmasoytisk preparat omfattende slike samt anvendelse av slike for fremstilling av farmasoytisk preparat for behandling av sykdom | |
JP2006506942A5 (fr) | ||
WO2006138745A3 (fr) | Peptides et vaccins therapeutiques | |
WO2006028561A3 (fr) | Nouveaux polypeptides fabi purifies issus de fransicella tularensis | |
WO2007093848A3 (fr) | Nouveaux polypeptides purifiés issus de helicobacter pylori | |
WO2004024072A3 (fr) | Nouvelles compositions et methodes pour le traitement de maladies associees au systeme immunitaire | |
WO2006074891A3 (fr) | Proteines contenant des lymphocytes t regulateurs et destinees au traitement et au diagnostic de maladies | |
WO2006016172A3 (fr) | Glycoproteine de surface | |
WO2007066018A3 (fr) | Peptides qui peuvent se lier a la proteine nef et leurs applications pharmaceutiques | |
WO2006043060A3 (fr) | Proteine contenant le domaine mam | |
WO2006010805A3 (fr) | Nouveaux polypeptides pour la mise en evidence in vitro et la prevention des infections a legionella pneumophila | |
SG156619A1 (en) | Novel cancer associated antibodies and antigens and their use in cancer diagnosis | |
WO2004053117A3 (fr) | Serine protease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06700003 Country of ref document: EP Kind code of ref document: A2 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 6700003 Country of ref document: EP |